Relief Therapeutics Holding AG (RLFTF)

[tcm55]

IV was for COVID only.?. The Inhaler is 3 X a day for 10 days, however 100ng takes for nebulizing per dose. 1/2 life of VIP is short, < 5minutes, so the long application seems necessary for the current formulations that are being used in all trials. ARDS and PF are endpoints now too in these later Trials. Dry Aviptadil is a while off from what I read...
Seems JJ et al are re-announcing presentation of the data with 60 day results included. A lot of NRXP volume yesterday, probably some from JJ/Dan and GEM/BRPA.
Who is speaking for RLF? When? EMA? Sub zero logistics?